Basic Information
| LncRNA/CircRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 |
| Ensemble | ENSG00000230316 |
| Refseq | NR_036484 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | breast cancer tissues, cell lines (MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-453) |
| Expression Pattern | up-regulated |
| Function Description | FEZF1-AS1 was up-regulated compared with controls and indicated poor prognosis of breast cancer patients. The expression of FEZF1-AS1 was correlated to Distant metastases, Lymphatic metastasis and TNM stage. In vitro experiments, FEZF1-AS1 was significantly over-expressed in breast cancer cells, especially in sphere subpopulation compared with parental subpopulation. Loss-of-functional indicated that, in BCSC cells (MDA-MB-231 CSC, MCF-7 CSC), FEZF1-AS1 knockdown reduced the CD44+ /CD24- rate, the mammosphere-forming ability, stem factors (Nanog, Oct4, SOX2), and inhibited the proliferation, migration and invasion. In vivo, FEZF1-AS1 knockdown inhibited the breast cancer cells growth. Bioinformatics analysis tools and series of validation experiments confirmed that FEZF1-AS1 modulated BCSC and Nanog expression through sponging miR-30a, suggesting the regulation of FEZF1-AS1/miR-30a/Nanog. |
| Pubmed ID | 29797562 |
| Year | 2018 |
| Title | Long Non-Coding RNA FEZF1-AS1 Promotes Breast Cancer Stemness and Tumorigenesis via Targeting miR-30a/Nanog Axis |
External Links
| Links for FEZF1-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |